Abbott Raises Full-Year EPS Guidance on Strong Q2 Performance
Event summary
- Abbott reported Q2 2026 sales growth of 13% on a reported basis and 4.8% on a comparable basis.
- Adjusted diluted EPS for Q2 2026 was $1.31, up from $1.26 in the previous year.
- Full-year 2026 adjusted diluted EPS guidance raised to $5.45-$5.60 from $5.38-$5.58.
- Completed enrollment in TECTONIC U.S. pivotal trial for Coronary Intravascular Lithotripsy (IVL) System.
- Secured CE Mark for Libre® Duo, a dual glucose-ketone biowearable sensor.
The big picture
Abbott's strong Q2 performance and raised guidance reflect strategic investments in diagnostics and medical devices. The company is leveraging acquisitions like Exact Sciences to bolster its portfolio while advancing regulatory milestones for innovative products. This positions Abbott to capitalize on growing demand for advanced healthcare solutions, particularly in emerging markets.
What we're watching
- Integration Success
- How Abbott will integrate Exact Sciences to drive long-term growth in diagnostics.
- Regulatory Milestones
- The pace at which Abbott secures FDA approval for Amulet™ 360 and other pending submissions.
- Market Expansion
- Whether Abbott can sustain momentum in emerging markets, particularly in Latin America and Asia Pacific.
Related topics